Skip to main content

Table 2 Comorbidities of patients hospitalized who underwent a mechanical mitral valve replacement in Spain from 2001 to 2015 according to type 2 diabetes status

From: Impact of type 2 diabetes mellitus in the utilization and in-hospital outcomes of surgical mitral valve replacement in Spain (2001–2015)

  T2DM 2001–2005 2006–2010 2011–2015 Total Trend
Mitral stenosis, n (%)* Yes 208 (12.68) 220 (10.94) 212 (10.09) 640 (11.12) 0.041
No 1212 (11.19) 999 (10.12) 768 (8.13) 2979 (9.88) < 0.001
Rheumatic mitral insufficiency, n (%)* Yes 72 (4.39) 70 (3.48) 83 (3.95) 225 (3.91) 0.368
No 428 (3.95) 418 (4.24) 475 (5.03) 1321 (4.38) 0.001
Mitral stenosis with insufficiency, n (%)* Yes 306 (18.66) 352 (17.5) 269 (12.8) 927 (16.11) < 0.001
No 1975 (18.23) 1663 (16.85) 1308 (13.84) 4946 (16.4) < 0.001
Chronic obstructive pulmonary disease, n (%)* Yes 142 (8.66) 161 (8.01) 176 (8.37) 479 (8.33) 0.774
No 695 (6.41) 641 (6.5) 600 (6.35) 1936 (6.42) 0.916
Peripheral vascular disease, n (%)* Yes 49 (2.99) 85 (4.23) 95 (4.52) 229 (3.98) 0.046
No 236 (2.18) 349 (3.54) 404 (4.28) 989 (3.28) < 0.001
Acute renal disease, n (%)* Yes 148 (9.02) 207 (10.29) 306 (14.56) 661 (11.49) < 0.001
No 744 (6.87) 1023 (10.37) 1422 (15.05) 3189 (10.58) < 0.001
Cerebrovascular disease, n (%)* Yes 94 (5.73) 111 (5.52) 120 (5.71) 325 (5.65) 0.952
No 468 (4.32) 423 (4.29) 503 (5.32) 1394 (4.62) < 0.001
Congestive heart failure, n (%) Yes 351 (21.4) 429 (21.33) 510 (24.26) 1290 (22.42) 0.040
No 2177 (20.09) 2023 (20.5) 2223 (23.52) 6423 (21.3) < 0.001
Atrial fibrillation, n (%)* Yes 969 (59.09) 1238 (61.56) 1298 (61.75) 3505 (60.92) 0.194
No 6152 (56.78) 5822 (59) 5549 (58.72) 17,523 (58.12) 0.002
Pulmonary hypertension, n (%)* Yes 513 (31.28) 626 (31.13) 632 (30.07) 1771 (30.78) 0.667
No 2846 (26.27) 2735 (27.72) 2648 (28.02) 8229 (27.29) < 0.001
Coronary artery disease, n (%)* Yes 445 (27.13) 516 (25.66) 571 (27.16) 1532 (26.63) 0.474
No 1818 (16.78) 1674 (16.97) 1788 (18.92) 5280 (17.51) < 0.001
Obesity, n (%)* Yes 157 (9.57) 224 (11.14) 306 (14.56) 687 (11.94) < 0.001
No 489 (4.51) 599 (6.07) 719 (7.61) 1807 (5.99) < 0.001
Cardiogenic shock, n (%)* Yes 53 (3.23) 65 (3.23) 67 (3.19) 185 (3.22) 0.996
No 387 (3.57) 414 (4.2) 415 (4.39) 1216 (4.03) 0.008
Gastrointestinal hemorrhage, n (%) Yes 6 (0.37) 7 (0.35) 3 (0.14) 16 (0.28) 0.333
No 52 (0.48) 41 (0.42) 34 (0.36) 127 (0.42) 0.417
Endocarditis, n (%) Yes 106 (6.46) 207 (10.29) 279 (13.27) 592 (10.29) < 0.001
No 815 (7.52) 986 (9.99) 1212 (12.83) 3013 (9.99) < 0.001
Pneumonia, n (%)* Yes 51 (3.11) 51 (2.54) 29 (1.38) 131 (2.28) 0.001
No 341 (3.15) 307 (3.11) 208 (2.2) 856 (2.84) < 0.001
Renal disease, n (%)* Yes 108 (6.59) 178 (8.85) 270 (12.84) 556 (9.66) < 0.001
No 430 (3.97) 529 (5.36) 669 (7.08) 1628 (5.4) < 0.001
Liver disease, n (%)* Yes 66 (4.02) 77 (3.83) 106 (5.04) 249 (4.33) 0.124
No 260 (2.4) 330 (3.34) 430 (4.55) 1020 (3.38) < 0.001
Cancer, n (%) Yes 13 (0.79) 23 (1.14) 21 (1) 57 (0.99) 0.566
No 72 (0.66) 98 (0.99) 99 (1.05) 269 (0.89) 0.007
Weight loss, n (%) Yes 8 (0.49) 6 (0.3) 13 (0.62) 27 (0.47) 0.321
No 38 (0.35) 41 (0.42) 39 (0.41) 118 (0.39) 0.699
  1. T2DM type 2 diabetes mellitus
  2. * p < 0.05 for comparisons between T2DM patients and non-T2DM patients